Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue GLP-1 Coverage Update: Prior Auth | O…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Coverage for GLP-1 Drug Class (Commercial & Medicare) — Prior Authorization and Documentation Requirements

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Florida Blue commercial and Medicare pharmacy coverage and prior authorization requirements for GLP-1 class drugs, limiting coverage to FDA-approved indications for type 2 diabetes and specifying documentation and drug-specific coverage rules for affected members and providers.

    Policy Summary
    PayerFlorida Blue
    PolicyCoverage for GLP-1 Drug Class (Commercial & Medicare)
    Policy CodePolicy N/A
    Change TypeCoverage updatedrug exclusiondocumentation requirement
    Effective DateApr 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical record documentation confirming type 2 diabetes and trials/failures of metformin or insulin.
    SourceLink
    POLICY UPDATE CHANGES

    Commercial prior authorization criteria now require clinical documentation of a type 2 diabetes diagnosis and documentation that the patient tried and failed metformin, metformin combinations, or insulin.

    Victoza is excluded from coverage for commercial plans effective April 1, 2024, with continuation allowed for current members until July 1, 2024.

    Medicare and Florida Blue do not cover GLP-1 medications when requested for weight loss/management; such requests will be denied.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-only
    Coverage limitation
    Victoza (comm)Drug-specific exclusion
    Until 2024-07-01Grandfathering
    Metformin/insulin trialPA clinical req
    Weight-loss deniedExcluded indication

    Coverage Criteria

    Initial approval criteria

    Covered when ALL of the following are met

    Commercial and Medicare GLP-1 coverage for diabetes: Patient has a documented diagnosis of type 2 diabetes; GLP-1 is being requested for an FDA‑approved indication for type 2 diabetes; documentation of trial and failure of metformin, metformin combination drugs, or insulin is provided.all

    Documentation must be submitted with the prior authorization request to Prime Therapeutics/myPrime.

    Florida Blue and Medicare do not cover GLP-1 medications when the request is for weight loss/weight management. Prior authorization is required for GLP-1 agents and will only be approved for FDA‑approved indications related to type 2 diabetes when supporting clinical documentation is provided. Providers must include medical record documentation of the patient’s type 2 diabetes diagnosis and evidence of prior trial and failure of metformin, metformin combination therapy, or insulin with the prior authorization submission; requests lacking this documentation will be denied.

    Victoza (liraglutide) is excluded from coverage for Florida Blue commercial plans effective 2024-04-01. Current commercial members on Victoza will be allowed continued coverage through July 1, 2024. Note that Medicare coverage differs; Victoza is listed as Medicare-covered in the source document and exclusion applies to commercial plans only.

    Requests for GLP-1 medications for indications other than type 2 diabetes — including weight loss or weight management — are considered not medically necessary and will be denied. Providers should inform patients that GLP-1 use for weight loss is not covered and must be paid out-of-pocket. Submissions to Prime Therapeutics/myPrime for weight-loss indications will result in denial and should be avoided to reduce administrative burden.

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization required. Prior authorization must be requested and will be approved only for FDA‑approved type 2 diabetes indications for GLP‑1 class drugs. Requests for off‑label uses (including weight‑loss/weight‑management indications such as Wegovy or Saxenda) will be denied.

    • Affects commercial and Medicare pharmacy coverage
    • Victoza excluded from commercial coverage as of 2024-04-01 (continued coverage for current commercial members through 2024-07-01)
    Step Therapy

    Step Therapy / Prior Treatment Requirement

    Step/step‑like requirement: Document prior therapy trials and failures. Providers must submit medical record documentation showing the patient tried and failed one of the following before GLP‑1 approval: metformin, a metformin combination product, or insulin.

    • Include dates, doses, and reason for discontinuation or inadequate response for prior therapies
    • Requests without documented prior trials of metformin/metformin combinations/insulin will be denied

    Definitions

    GLP-1 class definition — Glucagon-like Peptide-1 (GLP-1) receptor agonists
    TermGlucagon-like Peptide-1 (GLP-1) receptor agonists
    Class coverage stanceCovered only for FDA‑approved indications for treatment of type 2 diabetes
    Required documentationClinical documentation confirming a diagnosis of type 2 diabetes must be submitted with prior authorization requests
    Prior therapy requirementDocumentation that the patient tried and failed metformin, metformin combination drugs, or insulin is required
    Excluded usesRequests for weight loss/management (e.g., Wegovy, Saxenda) are excluded and will be denied
    Drug-specific noteVictoza is excluded for commercial plans effective April 1, 2024; current commercial members may continue coverage until July 1, 2024

    Background

    Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antihyperglycemic agents indicated for management of type 2 diabetes. Because several agents in this class have gained attention for weight-loss effects, Florida Blue clarifies coverage to align with Medicare regulations and clinical necessity: coverage is limited to FDA‑approved diabetes indications, and approvals require documentation of prior therapy failure with metformin, metformin combinations, or insulin. This approach ensures GLP-1 agents are used for supported diabetes indications and prevents coverage for off‑label weight‑loss uses.

    Initial Therapy Criteria

    Initial therapy criteria

    Initial authorization prerequisites

    Initial GLP-1 authorization: Must have a documented diagnosis of type 2 diabetes; provider must submit clinical documentation showing the patient tried and failed metformin, metformin combination therapy, or insulin; request must be for an FDA‑approved diabetes indication.all

    Include medical record documentation with the prior authorization request to Prime Therapeutics/myPrime; requests without required documentation will be denied.

    Continuation Criteria

    Continuation for Victoza

    Grandfathering for current members

    Victoza continuation: Current commercial members receiving Victoza will be allowed continued coverage through July 1, 2024.date

    As of April 1, 2024 Victoza is excluded for new commercial requests; after 7/1/2024 new and ongoing commercial claims for Victoza will be denied.

    Step Therapy / Prior Therapies

    Prior therapyRequirement
    MetforminDocumentation that the patient tried and failed metformin is required before GLP-1 approval will be considered.
    Metformin combination therapyDocumentation that the patient tried and failed other metformin combination drugs is required before GLP-1 approval will be considered.
    InsulinDocumentation that the patient tried and failed insulin is required before GLP-1 approval will be considered.
    Policy Summary
    PayerFlorida Blue
    PolicyCoverage for GLP-1 Drug Class (Commercial & Medicare)
    Policy CodePolicy N/A
    Change TypeCoverage updatedrug exclusiondocumentation requirement
    Effective DateApr 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical record documentation confirming type 2 diabetes and trials/failures of metformin or insulin.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions & RequirementsDefinitionsBackgroundInitial Therapy CriteriaContinuation CriteriaStep Therapy / Prior Therapies
    Documentation Required

    Documentation Required

    Required clinical documentation must be included with the authorization request. Submit medical records confirming a diagnosis of type 2 diabetes and documentation of the required prior therapies (metformin, metformin combinations, or insulin) and outcomes. If documentation is incomplete or absent, the request will be denied.

    • Provide clinical notes, lab results (e.g., A1C values), and medication history to support diagnosis and prior therapy attempts
    • For refill/continuation requests, include prior authorization history and rationale for ongoing therapy
    Denial Risk

    Denial Risk — Common Reasons

    Denial triggers: authorization requests will be denied for any of the following: no documented type 2 diabetes diagnosis; no documentation of required prior trials (metformin/metformin combinations/insulin); requests for weight‑loss/weight‑management indications; and off‑label uses.

    • Submitting a GLP‑1 request for weight‑loss/management will result in denial per Medicare regulations and Florida Blue policy
    • Requests for Victoza in commercial plans (after 2024-07-01) will be denied